FDA approves first RSV vaccine, a long-sought scientific achievement
The FDA on Wednesday licensed the first-ever vaccine for respiratory syncytial virus, or RSV, completing an elusive quest that has been decades in the making. The product, Arexvy, was approved for adults ages 60 and older and was developed by GSK, which beat a crowded field of competitors to cross the finish line first.
No comments